Alphabet Inc. is preparing to separate its life sciences subsidiary, Verily, in what could lead to a full sale or spinoff, according to recent testimony in a federal antitrust trial against Google. This effort aims to make Verily technologically independent, a crucial step for any potential sale or spinoff. While Alphabet has previously worked to reduce Verily’s reliance on Google systems, Thursday’s testimony represents the clearest signal yet that Alphabet is preparing to cut ties with the unit. The Justice Department’s case against Google centers on alleged monopolistic practices, and Adkins’ testimony offered a rare glimpse into Alphabet’s broader restructuring plans. The potential spinoff underscores Alphabet’s evolving strategy of streamlining its business while allowing innovative subsidiaries like Verily to pursue independent growth paths in competitive industries.